Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Capital Expenditures (2023 - 2024)

Lexicon Pharmaceuticals (LXRX) has disclosed Capital Expenditures for 5 consecutive years, with $474000.0 as the latest value for Q4 2024.

  • Quarterly Capital Expenditures changed N/A to $474000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $781000.0 through Dec 2025, down 24.25% year-over-year, with the annual reading at $1.0 million for FY2024, 119.36% up from the prior year.
  • Capital Expenditures for Q4 2024 was $474000.0 at Lexicon Pharmaceuticals, up from $307000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $474000.0 in Q4 2024, with the low at $83000.0 in Q3 2023.